Company: SONM
Filing Date: 2025-08-27
Form Type: 8-K
Source: 0001641172-25-025693
Chunk: 0

Company: SONIM TECHNOLOGIES INC
Filing Date: 2025-08-27
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On
August 22, 2025, Sonim Technologies, Inc. (the “ Company”) received a letter (the “ Deficiency Letter”) from The
Nasdaq Stock Market LLC (“ Nasdaq”) indicating that the Company’s stockholders’ equity, as reported in its Quarterly
Report on Form 10-Q for the period ended June 30, 2025 (the “ Form 10-Q”), did not satisfy the continued listing requirement
under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’
equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was
$1,334,000. Additionally, the Deficiency Letter stated that as of August 21, 2025, the Company did not meet the alternatives of market
value of listed securities of $35.0 million per Listing Rule 5550(b)(2) or net income from continuing operations of $0.5 million in its
most recently completed fiscal year or in two of its three most recently completed fiscal years per Listing Rule 5550(b)(3), and as such,
the Company did not comply with the Listing Rule 5550 for continued listing on the Nasdaq Capital Market. The Deficiency Letter has no
immediate effect on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market
under the symbol “ SONM.”

In
accordance with Nasdaq Listing Rule 5810(c)(2)(C), the Company has been provided an initial period of 45 calendar days, or until October
6, 2025, to submit a plan to regain compliance. Subsequent to the receipt of the Deficiency Letter, and prior to that deadline, the Company
will submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1) to Nasdaq. If the Company’s plan is accepted, Nasdaq
may grant an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance.

The
Company is currently evaluating various courses of action to regain compliance and plans to timely submit its plan to Nasdaq to regain
compliance with Nasdaq Listing Rule 555